Phase 2/3 trial in treatment-refractory Mycobacterium avium Complex continues with Phase 2 topline results expected in summer 2024 and Phase 3 enrollment pause in place during continued analysis of.
PG A.M.: Takeaways from Georgia's presidential primaries ajc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ajc.com Daily Mail and Mail on Sunday newspapers.
TrippBio Publishes Data Comparing the in vitro and in vivo Activity of PanCytoVir™ versus Oseltamivir einnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from einnews.com Daily Mail and Mail on Sunday newspapers.
Trippbio Presents At The World Vaccine Congress West Coast 2023 Meeting menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
Enrollment well underway in Phase 3 part of pivotal Phase 2/3 study of epetraborole in treatment-refractory Mycobacterium avium complex lung disease
On track to announce Phase 2 clinical data.